Halozyme Therapeutics Return on Equity

Halozyme Therapeutics (HALO) currently reports a ROE of 158.83%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore Halozyme Therapeutics's ROE history and peer comparisons.

Halozyme Therapeutics's ROE of 158.83% is higher than the Healthcare sector average of 29.33%. That is roughly 441.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Halozyme Therapeutics's current 158.83% should be judged against Healthcare norms (sector average: 29.33%) and against HALO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 158.83%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Halozyme Therapeutics, and consider following HALO for alerts when major investors trade the stock.

Halozyme Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 158.83% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HALO with unrelated industries.